130 related articles for article (PubMed ID: 31983093)
1. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.
Zhao J; Yu H; Han T; Wang W; Tong W; Zhu X
J BUON; 2019; 24(6):2267-2272. PubMed ID: 31983093
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of
Advanced Lung Squamous Carcinoma].
Lv Y; Jiang R; Ma C; Li J; Wang B; Sun L; Mu N
Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):500-4. PubMed ID: 26302347
[TBL] [Abstract][Full Text] [Related]
4. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.
Chen L; Zhu X; Li D; Cai X
J BUON; 2020; 25(6):2643-2649. PubMed ID: 33455108
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
[TBL] [Abstract][Full Text] [Related]
8. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
Liu Z; Ou W; Li N; Wang SY
Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
[TBL] [Abstract][Full Text] [Related]
9. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
10. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
[TBL] [Abstract][Full Text] [Related]
11. Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases.
Jiang XD; Ding MH; Qiao Y; Liu Y; Liu L
Clin Lung Cancer; 2014 Mar; 15(2):e23-9. PubMed ID: 24374073
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
[TBL] [Abstract][Full Text] [Related]
13. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer].
Yang L; Wang JW; Sun Y; Zhu YZ; Liu XQ; Li WL; Di LJ; Li PW; Wang YL; Song SP; Yao C; You LF
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):138-41. PubMed ID: 16750022
[TBL] [Abstract][Full Text] [Related]
14. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
16. [Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].
Xing P; Hao X; Hu X; Wang Y; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):670-674. PubMed ID: 27760596
[TBL] [Abstract][Full Text] [Related]
17. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer.
Li J; Tong X; Li H
Indian J Cancer; 2020; 57(1):13-17. PubMed ID: 32129295
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model.
Jin Y; Wei L; Jiang Q; Song X; Teng C; Fan C; Lv Y; Liu Y; Shen W; Li L; Huang D; Xin T
Sci Rep; 2018 Oct; 8(1):15837. PubMed ID: 30367145
[TBL] [Abstract][Full Text] [Related]
20. An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving gene(s).
Fan S; Zou Y; Wang Y; Fang F; Song W
J BUON; 2018; 23(3):654-658. PubMed ID: 30003733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
